Physician profile
Lindsey Lee
NPI 1477216802
$1,079.75
in general payments reported to CMS, 2019-2025
20 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.67 · 2022: $302 · 2023: $160 · 2024: $243 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $764.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $304.94 | 2022-2025 | Bexsero, Shingrix |
| Tris Pharma INC | $157.26 | 2021-2025 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $73.05 | 2025 | Jornay Pm |
| Sanofi-Aventis U.S. LLC | $61.01 | 2025 | |
| Merck Sharp & Dohme LLC | $58.39 | 2024-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Corium, LLC | $53.74 | 2022-2023 | Azstarys |
| Ironshore Pharmaceuticals INC. | $52.53 | 2022-2024 | |
| Pfizer INC. | $50.47 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.89 | 2022-2025 | Elaprase |
| Kaleo, INC. | $30.93 | 2022 | |
| Novo Nordisk INC | $24.55 | 2024 | |
| Verrica Pharmaceuticals INC. | $24.27 | 2024 | Ycanth |
| Sobi, INC | $21.33 | 2022 | |
| Noven Therapeutics, LLC | $21.02 | 2024 | Secuado, Xelstrym |
| Astrazeneca Pharmaceuticals LP | $20.09 | 2024 | Flumist Quadrivalent |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $18.50 | 2025 | Doc Band |
| Lnhc, INC | $18.01 | 2025 | Zelsuvmi |
| Supernus Pharmaceuticals, INC. | $17.99 | 2025 | Qelbree |
| Neurelis, INC. | $14.65 | 2023 | Valtoco |
| Seqirus USA INC | $14.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.